IL140858A0 - Endogenous constitutively activated g protein-coupled orphan receptors - Google Patents

Endogenous constitutively activated g protein-coupled orphan receptors

Info

Publication number
IL140858A0
IL140858A0 IL14085899A IL14085899A IL140858A0 IL 140858 A0 IL140858 A0 IL 140858A0 IL 14085899 A IL14085899 A IL 14085899A IL 14085899 A IL14085899 A IL 14085899A IL 140858 A0 IL140858 A0 IL 140858A0
Authority
IL
Israel
Prior art keywords
protein
constitutively activated
orphan receptors
endogenous constitutively
coupled orphan
Prior art date
Application number
IL14085899A
Other languages
English (en)
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Priority to IL16044699A priority Critical patent/IL160446A0/xx
Publication of IL140858A0 publication Critical patent/IL140858A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/42Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL14085899A 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors IL140858A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL16044699A IL160446A0 (en) 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9487998P 1998-07-31 1998-07-31
US10630098P 1998-10-30 1998-10-30
US11090698P 1998-12-04 1998-12-04
US12185199P 1999-02-26 1999-02-26
PCT/US1999/017425 WO2000006597A2 (en) 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors

Publications (1)

Publication Number Publication Date
IL140858A0 true IL140858A0 (en) 2002-02-10

Family

ID=27492754

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14085899A IL140858A0 (en) 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors

Country Status (13)

Country Link
EP (1) EP1095275B1 (enExample)
JP (1) JP2002521681A (enExample)
CN (1) CN1231762C (enExample)
AT (1) ATE432472T1 (enExample)
AU (1) AU751080B2 (enExample)
CA (1) CA2338543C (enExample)
DE (1) DE69940923D1 (enExample)
DK (1) DK1095275T3 (enExample)
IL (1) IL140858A0 (enExample)
MX (1) MXPA01001176A (enExample)
NO (1) NO20010509L (enExample)
NZ (1) NZ509429A (enExample)
WO (1) WO2000006597A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
MXPA02009902A (es) 2000-04-07 2003-06-17 Arena Pharm Inc Receptores acoplados a proteina g, conocidos, activados constitutivamente, no endogenos.
AU2003218234A1 (en) * 2002-03-15 2003-09-29 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
WO2003081256A2 (en) * 2002-03-22 2003-10-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled orphan receptor 21 (gpr21)
WO2004015422A2 (en) * 2002-08-05 2004-02-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)
CA2511144A1 (en) * 2002-12-20 2004-07-08 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2005095990A1 (en) * 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 52 (gpr52)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220715C (en) * 1995-06-07 2004-11-02 Praecis Pharmaceuticals Incorporated Functional bioassay for g-protein coupled receptor agonists and antagonists
WO1997011159A1 (en) * 1995-09-20 1997-03-27 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
NZ336479A (en) * 1997-04-14 2001-10-26 Arena Pharm Inc A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease

Also Published As

Publication number Publication date
DK1095275T3 (da) 2009-09-28
JP2002521681A (ja) 2002-07-16
CN1323396A (zh) 2001-11-21
MXPA01001176A (es) 2005-07-25
NZ509429A (en) 2002-06-28
AU751080B2 (en) 2002-08-08
WO2000006597A9 (en) 2000-07-13
DE69940923D1 (de) 2009-07-09
NO20010509L (no) 2001-03-19
WO2000006597A2 (en) 2000-02-10
ATE432472T1 (de) 2009-06-15
CA2338543A1 (en) 2000-02-10
EP1095275A2 (en) 2001-05-02
AU5545999A (en) 2000-02-21
WO2000006597A3 (en) 2000-05-18
CN1231762C (zh) 2005-12-14
EP1095275B1 (en) 2009-05-27
CA2338543C (en) 2009-12-29
NO20010509D0 (no) 2001-01-30

Similar Documents

Publication Publication Date Title
MY127234A (en) Methods for assessing, improving, or maintaining urogenital health in postmenopausal women
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
EP1461061A4 (en) COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS
NO20024221D0 (no) Blandinger inneholdende alfa-2-adrenerge agonistkomponenter
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
DE69711519D1 (de) Carbazolanaloge als selektive beta3-adrenergische Agonisten
AUPO755097A0 (en) Receptor agonist and antagonist
PT935465E (pt) Compostos novos de imidazole substituido
DE69903953D1 (de) 2-substituierte-1-piperidyl-benzimidazolverbindungen als orl1 rezeptor agonisten
DE69901714D1 (de) Elektrochemischer affinitätsassay
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
BR0007864A (pt) Composto, e, uso de um composto
MX9801987A (es) Nuevos derivados de aminoacido, su obtencion y su uso.
BR0113321A (pt) Combinação farmacêutica de antagonistas de angiotensina ii e inibidores da enzima conversora de angiotensina i
IL140858A0 (en) Endogenous constitutively activated g protein-coupled orphan receptors
BR0108454A (pt) Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos
CO5460266A1 (es) Novedosos analogos de la somatostatina
WO2004108887A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
UA97346C2 (ru) Стабильная эмульсионная композиция
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
BR0110450A (pt) Uso de agonistas receptores d4 de dopamina seletivo para tratamento de disfunção sexual
NO990849L (no) Substituerte 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyklohepta (b) benzofuraner
ES2191625T3 (es) Composicion oral que contiene perlita.